We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App





DiaSorin Showcases Latest Assays and Reagents for In-Vitro Diagnostics

By LabMedica International staff writers
Posted on 22 May 2023

DiaSorin S. More...

p.A. (‎Saluggia‎, Italy) is exhibiting its range of advanced diagnostic solutions at this year's WorldLab-EuroMedLab that are designed to help clinicians in the management of emergency patients.

At EuroMedLab Rome 2023, DiaSorin is presenting its industry-leading offering of fully-automated chemiluminescent immunoassay (CLIA) panels, designed specifically for diagnosing infectious diseases. The highlight of the event, however, is the LIAISON MeMed BV test - DiaSorin's groundbreaking solution for rapidly and accurately distinguishing between bacterial and viral infections. The LIAISON MeMed BV test is the first of its kind, a fully automated solution that uses data based on the host's response. This innovative test aids physicians in accurately distinguishing between bacterial and viral infections, thereby facilitating quicker, more informed decisions regarding treatment and patient management. Moreover, compared to conventional growth-based microbiology methods, this test enhances lab operational efficiency by saving time and reducing labor through its fully automated and high-throughput approach.

In addition, DiaSorin is highlighting the capabilities of its LIAISON XS analyzer - a high-tech solution for immunochemistry tests. The analyzer enables laboratories to boost both efficiency and clinical effectiveness for routine and specialty testing. Also on display at the event is the LIAISON XL, a fully automated chemiluminescence analyzer, designed to carry out complete sample processing (including sample pre-dilutions, sample and reagent dispensing, incubations, wash processes, etc.), measurement, and evaluation. The LIAISON XL, with its innovative features such as a fully automated solution, superior result quality, flexible configuration, and high efficiency, has the potential to significantly improve the productivity of immunoassay labs.

Related Links:
DiaSorin S.p.A.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.